ホーム › 急性骨髄性白血病 › オレゴン › Portland
Portland、ORにおける急性骨髄性白血病の臨床試験
Portlandとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する25件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
被験者募集中第1相
- OHSU Knight Cancer Institute, Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12マイル先
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
被験者募集中第1相
- OHSU Knight Cancer Institute, Portland
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
被験者募集中第2相
- OHSU Knight Cancer Institute, Portland
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
被験者募集中第1/2相
- Oregon Health & Science University, Portland
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
被験者募集中第1/2相
- Oregon Health and Science University, Portland
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
被験者募集中第3相
- US-Portland OR-OHSU, Portland
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- Doernbecher Children's Hospital, Portland
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
被験者募集中第3相
- Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
被験者募集中第1相
- OHSU Knight Cancer Institute, Portland
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
被験者募集中第2相
- OHSU Knight Cancer Institute, Portland
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
被験者募集中第2相
- Oregon Health and Science University, Portland
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Oregon Health & Science University/Doernbecher Children's Hospital, Portland
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
被験者募集中第1相
- OHSU Knight Cancer Institute, Portland
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
被験者募集中第2/3相
- Oregon Health and Science University, Portland
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
被験者募集中第2相
- Oregon Health & Science University, Portland
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
被験者募集中第1相
- OHSU, Portland
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
被験者募集中健康なボランティア歓迎
- Oregon Health & Science University, Portland
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Seattle, WA41件の研究
- Baldwin Park, CA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA31件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Washington, DC24件の研究
Portlandにおける他の研究
- 非小細胞肺癌46件の研究
- がん（全種類）34件の研究
- 乳がん33件の研究
- 前立腺がん33件の研究
- 転移性癌29件の研究
- 大腸癌28件の研究
- 卵巣がん27件の研究
- 肺がん26件の研究
- 子宮内膜がん24件の研究
- 頭頸部扁平上皮癌19件の研究
- 膵臓がん19件の研究
- 心不全17件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。